Q4 2024 EPS Estimates for Quest Diagnostics Incorporated Lowered by Analyst (NYSE:DGX)

Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Analysts at Zacks Research dropped their Q4 2024 EPS estimates for shares of Quest Diagnostics in a report released on Monday, May 13th. Zacks Research analyst M. Mondal now expects that the medical research company will post earnings of $2.15 per share for the quarter, down from their prior estimate of $2.29. The consensus estimate for Quest Diagnostics' current full-year earnings is $8.78 per share. Zacks Research also issued estimates for Quest Diagnostics' Q1 2025 earnings at $2.13 EPS, Q2 2025 earnings at $2.41 EPS, Q3 2025 earnings at $2.40 EPS, FY2025 earnings at $9.27 EPS, Q1 2026 earnings at $2.33 EPS and FY2026 earnings at $10.08 EPS.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion during the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The business's quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.04 earnings per share.

Several other research firms also recently issued reports on DGX. Citigroup boosted their price objective on Quest Diagnostics from $135.00 to $145.00 and gave the stock a "neutral" rating in a report on Wednesday, April 24th. TheStreet downgraded shares of Quest Diagnostics from a "b-" rating to a "c" rating in a research report on Monday, February 5th. Mizuho boosted their target price on shares of Quest Diagnostics from $150.00 to $155.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. UBS Group raised their target price on Quest Diagnostics from $139.00 to $146.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 24th. Finally, Leerink Partnrs reissued a "market perform" rating on shares of Quest Diagnostics in a research report on Monday, February 26th. Ten investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $146.17.

Quest Diagnostics Trading Down 1.2 %

Shares of NYSE DGX traded down $1.62 during mid-day trading on Tuesday, hitting $139.16. 741,077 shares of the company traded hands, compared to its average volume of 1,038,536. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. Quest Diagnostics has a 1 year low of $119.59 and a 1 year high of $145.58. The stock has a market capitalization of $15.46 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 3.01 and a beta of 0.88. The business has a 50 day moving average of $132.09 and a two-hundred day moving average of $132.46.

Insider Transactions at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the completion of the sale, the senior vice president now owns 40,206 shares of the company's stock, valued at approximately $5,071,584.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 661 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the sale, the senior vice president now owns 40,206 shares of the company's stock, valued at $5,071,584.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicky B. Gregg sold 2,500 shares of Quest Diagnostics stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $126.64, for a total transaction of $316,600.00. Following the completion of the transaction, the director now directly owns 16,329 shares in the company, valued at approximately $2,067,904.56. The disclosure for this sale can be found here. Insiders have sold a total of 16,910 shares of company stock worth $2,159,602 in the last 90 days. 0.79% of the stock is owned by insiders.

Institutional Investors Weigh In On Quest Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in Quest Diagnostics by 2.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,910 shares of the medical research company's stock worth $5,595,000 after buying an additional 1,281 shares during the period. Park Avenue Securities LLC acquired a new stake in Quest Diagnostics in the 3rd quarter worth $506,000. Assetmark Inc. increased its holdings in shares of Quest Diagnostics by 31.7% during the 3rd quarter. Assetmark Inc. now owns 5,089 shares of the medical research company's stock worth $620,000 after purchasing an additional 1,224 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Quest Diagnostics by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 9,707 shares of the medical research company's stock valued at $1,183,000 after buying an additional 108 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Quest Diagnostics by 132.5% in the third quarter. Teacher Retirement System of Texas now owns 19,667 shares of the medical research company's stock valued at $2,397,000 after buying an additional 11,208 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.